Smith & Nephew
About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Employees: 17,349
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 3 (+2) [Q2]
52% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 25
51% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 67
16% more capital invested
Capital invested by funds: $891M [Q1] → $1.04B (+$145M) [Q2]
4% more funds holding
Funds holding: 222 [Q1] → 231 (+9) [Q2]
0.27% more ownership
Funds ownership: 3.59% [Q1] → 3.86% (+0.27%) [Q2]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Canaccord Genuity
Caitlin Cronin
|
$36
|
Hold
Maintained
|
18 Aug 2025 |
Financial journalist opinion
Based on 5 articles about SNN published over the past 30 days
